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ABSTRACT 
Gastric cancer is the second most common cause of cancer-related mortality in the world. 
The mechanisms of gastric carcinogenesis are not fully elucidated. Telomerase and its 
catalytic subunit telomerase reverse transcriptase (hTERT) are aberrantly activated in 
gastric cancer cells and their activation disrupts a major malignant transformation barrier, 
namely cellular senescence and contributes to immortalization of gastric cells. In order to 
get further insights into the mechanisms of gastric carcinogenesis, we examined the role 
of two novel factors. In study I, the expression and function of the ATPase Reptin in 
gastric cancer were assessed. Reptin was up regulated in gastric cancer samples and 
required for the transcription of the hTERT gene by cooperating with c-Myc. Depletion of 
Reptin impaired the clonogenic potential of gastric cancer cells. In study II, the role of 
the transcription factor FoxM1 in gastric cancer was evaluated. Forkhead box protein M1 
(FoxM1) was overexpressed in gastric cancer samples. Its inhibition led to cellular 
senescence and loss of clonogenic potential of gastric cancer cells. The induction of 
senescence was mediated by the p27kip signaling pathway. hTERT transcription and 
telomerase activity were also inhibited by FoxM1 depletion. In summary, these studies 
show the aberrant expression and function of Reptin and FoxM1 in gastric cancer and 
their potential as targets for gastric cancer therapy. 
Prostate cancer is one of the most frequent malignancies and the second leading cause of 
cancer-related deaths in men in western countries. Its development is associated with the 
over-activation of androgen receptor- and tyrosine kinase-dependent signaling cascades in 
prostate cells. One of the biggest obstacles in the clinical management of prostate cancer 
is the development of resistance to hormone deprivation therapy. Several tyrosine kinase 
inhibitors (TKIs), including the multi-tyrosine kinase inhibitor sorafenib, are now in 
clinical trials as novel therapeutics for prostate cancer. In study III, we examined the 
mechanisms of cell death induced by sorafenib in prostate cancer cell lines. It was found 
that sorafenib can induce caspase-dependent cell death in the prostate cancer cell lines, 
22RV1 and PC3.  Importantly, we found that different signaling cascades were targeted 
by sorafenib in 22RV1 and PC3 cells that may determine the cytotoxic efficacy of the 
drug. Furthermore, the maximal cytotoxic efficacy of this TKI was attenuated by the 
induction of cytoprotective autophagy in these cell lines. Combination of sorafenib with 
the Bcl-2 antagonist ABT737 enhanced the cytotoxic efficacy of sorafenib. Interestingly, 
this combination can reverse the protection mediated by primary cancer associated 
fibroblasts against sorafenib-induced cell death in prostate cancer cells.  In study IV, 
ATG5-independent autophagy in cancer cells was described. Treatment with sorafenib 
can induce mitochondria depolarization and damage in these cells. The ensuing induction 
of autophagy restored partially the mitochondria potential but did not rescue the cells 
from death. In fact, we found that the induced autophagy was cytotoxic due to lack of 
expression of the autophagy key regulator ATG5. Interestingly, loss of expression of 
ATG5 was also observed in prostate cancer tissue samples. In summary, these studies 
provide further insights on the mechanisms of cell death induced by the TKI sorafenib in 
the prostate cancer setting.  
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1. Introduction 
     1.1 Hallmarks of cancer 
 
Figure 1. Hallmarks of cancer. Reprinted from Hanahan and Weinberg, 2011, with 
permission from Elsevier. 
The four studies in this thesis have focused on certain hallmarks of gastric and prostate 
cancer. In 2011, Hanahan and Weinberg revised their original set of  hallmarks of cancer 
and introduced to the six original hallmarks (i.e. sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, activating invasion and metastasis) two emerging hallmarks (i.e. 
deregulated cellular energetics and avoiding immune destruction) and two enabling 
characteristics (i.e. genomic instability and tumor promoting inflammation).1 
Solid tumors are neoplasms composed of proliferating tumor cells. Sustained 
proliferation is the most prominent characteristic of cancer cells. Sustained growth of 
tumor cells can be due to several reasons: deregulated autocrine and paracrine 
proliferation signals, overexpression of growth factor receptors (e.g. overexpression 
hepatocyte growth factor receptor c-Met in gastric cancer) or activating mutations of 
downstream factors (e.g. phosphatidylinositol 3-kinase (PI3K) mutation in prostate 
cancer). Furthermore, loss of negative-feedback loops further promotes the constitutive 
proliferation of cancer cells (e.g. loss of phosphatase and tensin homolog (PTEN) in 
prostate cancer).1  
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Evading growth suppressors is another strategy utilized by cancer cells to sustain 
constitutive proliferation. Retinoblastoma gene Rb and p53 are two important growth 
suppressors which can be inactivated in tumor cells by different mechanisms. Loss of 
expression of proteins regulating cell cycle check points promotes tumor development. In 
prostate cancer, for example, loss of p27kip can lead to inhibition of senescence and 
progression from prostatic neoplasia to prostate cancer.2 
Resistance to cell death induced either by intracellular or extracellular cytotoxic stimuli 
is a major hallmark of carcinogenesis and tumor progression.  There are different modes 
of cell death: apoptosis (type I programmed cell death), autophagy (type II programmed 
cell death), necrosis (type III programmed cell death) and mitotic catastrophe. Tumor 
cells can avoid apoptosis by up-regulating oncogenic pathways such as PI3K-AKT 
pathway that inactivate downstream cell death effectors [e.g. Bcl-2-associated death 
promoter (Bad), caspase-9] or by overexpressing anti-apoptotic Bcl-2 members such as 
B-cell lymphoma 2 (Bcl-2), myeloid cell leukemia-1 (Mcl-1) and B-cell lymphoma-extra-
large (Bcl-xL). Importantly, induction of cell death is an important strategy to eliminate 
tumor cells by anti-cancer treatments. Thus, one mechanism of acquisition of resistance to 
cancer treatment is the inactivation of the cell death pathways. This topic will be further 
discussed in the chapter 1.9. 
Enabling replicative immortality allows cancer cells to achieve infinite growth. The 
role of telomerase in the acquisition of unlimited proliferative potential has been well 
established. This topic will be further discussed in the chapter 1.3.  
Infinite growth and sustained proliferation of cancer cells lead to the expansion of the 
tumor mass. This also increases the demand of tumor cells for oxygen and nutrient supply. 
Tumor cells can only grow to 1-2 mm3 without angiogenesis. During carcinogenesis, 
angiogenesis is induced in order to sustain nutrient and oxygen supply to the neoplastic 
mass. Vascular endothelial growth factor (VEGF) is one of the key regulators of 
angiogenesis.3 It is involved in the carcinogenesis of different types of cancer and is a 
target for anti-cancer treatment.   
Activating invasion and metastasis is involved in the later steps of tumor progression. 
Several mechanisms such as epithelial–mesenchymal transition (EMT) can contribute to 
the acquisition of mobility of tumor cells. Tumor cells break the barrier of basal 
membrane, degrade extracellular matrix, migrate and establish colonies at distant 
metastatic sites. 
Genomic instability is characteristic of most human cancers.4, 5 Genomic instability can 
be caused, for example, by base pair mutations and chromosomal deletions or 
translocations.  Base pair mutation or depletion silences tumor suppressor gene, and DNA 
damage repair machinery. Chromosome translocation can lead to aberrant oncogene 
expression. TMPRSS2-ERG created by gene fusion is a key factor in prostate cancer 
development. 
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The paradigm that tumor promoting inflammation can increase the predisposition of 
certain malignancies is nowadays widely accepted. Pro-carcinogenic inflammation can be 
caused by infections. For example, H.pylori infection is associated with the development 
of gastric cancer.6 The progression from inflammation to carcinogenesis can be due to 
different reasons, for example DNA damage caused by reactive oxygen specifies (ROS) 
generated by H.pylori, infiltrating inflammatory cells and growth factor-driven cell 
proliferation. 
 
Reprogramming of cancer cell metabolism is an emerging hallmark of cancer.7 In 
cancer cells, metabolism is switched from oxidative phosphorylation to glycolysis which 
is 18 times less efficient in terms of ATP production. The reprogramming of cancer cells 
to obtain their energy from alternative energy sources such as aerobic glycolysis is known 
as the Warburg effect.8 One of the main signaling pathways involved in this 
reprogramming is the PI3K-AKT/mammalian target of RapaMycin (mTOR) which is 
activated in a variety of human malignancies including gastric and prostate cancer. In 
cancer cells, several key metabolic enzymes are involved in tumor development. For 
example, hexokinase II which is required for the phosphorylation of glucose to glucose-6-
phosphate can promote tumor cell survival by suppressing cell death.9 
 
Immune surveillance is a crucial mechanism to eradicate malignant cells. Cancer cells 
have devised several ways to evade immune destruction. For example, by impairing 
antigen presentation e.g. mutations of the antigen; secreting immunosuppressive factors 
like transforming growth factor β (TGF-β)10 and interleukin 1011. 
 
In the first two studies on gastric cancer, two novel factors Reptin and FoxM1 are 
examined, which provide insights into the mechanism of gastric cancer development. In 
the two studies on prostate cancer we delineated the cell death mechanisms induced by 
the multi-tyrosine kinase inhibitor sorafenib.  
1.2 Gastric cancer  
1.2.1 Introduction  
Gastric cancer is a neoplasm derived from the stomach. It is the fourth most common 
cancer type and the second highest cause of cancer-related mortality in the world.12 Japan, 
China, Latin America, parts of Eastern Europe have more gastric cancer-related deaths 
compared to other areas in the world. The geographic pattern of gastric cancer incidence 
is related with socio-economic state, and infection of H.pylori.13 Predisposing risk factors 
of gastric cancer include H.pylori infection, smoking, obesity and diet. For example salty 
diet and low fruit/vegetables intake can increase the risk of gastric cancer. Furthermore, 
males have higher frequency of developing gastric cancer than females.14 Genetic 
polymorphisms are also associated with gastric cancer.15  
Most of gastric cancers are adenocarcinomas. Gastric adenocarcinomas can be divided 
into two major histological types- diffuse type and intestinal type.16 The intestinal type of 
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gastric cancer develops from chronic gastritis to intestinal metaplasia to dysplasia and 
finally invasive carcinoma. 
          
Figure 2. Role of H.pylori in gastric cancer. H.pylori can induce gastric cancer by secreting 
bacterial virulence factors and recruiting bone marrow-derived progenitor cells. 
Gastroscopy examination is a useful tool in the early detection of gastric dysplasia and 
gastric adenocarcinoma. The prognosis of early gastric cancer is relatively good with 70-
95% five-year survival rate. Clinical stage IV gastric cancer with metastases is associated 
with poor prognosis. Surgical resection is the primary treatment modality for gastric 
cancer. Alternative or additional treatments include adjuvant chemotherapy and 
radiotherapy.  
1.2.2 Molecular mechanisms of gastric cancer  
The mechanisms of gastric cancer development are not fully elucidated yet. Inflammation, 
genetic and epigenetic regulations of oncogenes and tumor suppressor genes are thought 
to play roles in the pathogenesis of gastric cancer.17 
Development of gastric cancer is closely related to the chronic inflammation caused by 
H.pylori infection.6 H.pylori is a pathogen that colonizes the stomach of more than half of 
the human population. Persistent infection with H.pylori can induce gastritis and is 
associated with the development of peptic ulcer, gastric mucosa-associated lymphoid 
tissue (MALT) lymphoma and gastric adenocarcinoma.6 Mechanisms of H.pylori induced 
gastric cancer include bacterial virulence factors, chronic inflammation, and recruitment 
of bone marrow progenitor cells. H.pylori secretes several bacterial virulence factors 
Stomach 
H.pylori 
Bacterial virulence factors:  
e.g. CagA Bone marrow derived  
progenitor cells 
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including CagA which can activate the nuclear factor kappa B (NF-κB) signaling cascade. 
Bone marrow-derived progenitor cells (BMDC) were proposed to be the origin of gastric 
cancer cells in gastric adenocarcinoma induced by H.pylori infection.18 These 
undifferentiated precursor cells were recruited to repair the lesion caused by H.pylori 
infection and further contributed to the development of dysplasia and intraepithelial 
neoplasia lesions. 18  
Deregulation of oncogenes and tumor suppressor genes is also implicated in the 
development of gastric cancer. Loss of adenomatous polyposis coli (APC) tumor 
suppressor gene is one of the early events during gastric carcinogenesis and found in 20% 
of differentiated gastric carcinomas.19 Runt-related transcription factor 3 (RUNX3) is a 
tumor suppressor which is frequently down-regulated in gastric cancer.20 In 45% to 60% 
of human gastric cancer, RUNX3 is silenced due to gene deletion or hyper-methylation of 
its promoter region.20 There are multiple mechanisms by which the loss of RUNX3 
expression promotes gastric cancer. RUNX3 has been shown to induce apoptosis of 
gastric cancer cells by activating Bim under cooperation with the PI3K-AKT signaling 
pathway component FoxO3a/FKHRL1.21, 22 RUNX3 also suppresses cell proliferation by 
activating p21cip1 signaling.23  
Oncogene activation plays an essential role in the pathogenesis of gastric cancer. The 
overexpression of c-Met, the receptor of hepatocyte growth factor (HGF), correlates with 
advanced stages of gastric cancer and worse prognosis.24 Compared to tumors without 
liver metastases, c-Met was expressed at higher level in stage IV gastric cancer with liver 
metastasis.25 The human telomerase enzyme catalytic subunit hTERT is also up-regulated 
during the development of gastric cancer.26 In more than 90% of gastric cancer tissue 
telomerase activity was detected. 26  
1.3 Telomerase  
                     
 
Figure 3. Structure of the telomere. Telomere is a structure in the end of eukaryotic 
chromosome. Telomere struture is charisterised by a T-loop. It is formed by the DNA 3´-end 
overhang intruding into telomere duplex DNA. TRF (Telomere repeat binding factor) as telomere 
binding protein binds with telomere duplex DNA and regulates telomere length. 
Telomere 
T-loop  
5' 
TRF 
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1.3.1 Introduction of telomere and telomerase               
The telomere is a complex located at the end of eukaryotic chromosomes. It is comprised 
of conserved TTAGGG tandem repeats and telomere binding proteins. The physiological 
function of telomere is to sustain chromosome stability. Because of the end replication 
problem of conventional DNA polymerase, the lagging strand of DNA gets shorter in the 
5´ end during each round of cell division. When the erosion of telomeres reaches the 
critical point, cells go to a permanent quiescence state or senescence. Senescent cells 
cannot re-enter the cell cycle, do not proliferate but are metabolically active. Loss of the 
telomere can cause chromosome end-to-end fusion which is recognized as a DNA 
damage signal. So the telomeres can serve as a biological clock and their length reflects 
the replicative potential of the cells. Telomere DNA is bound by single and double strand 
telomere binding proteins. Telomere repeat binding factor 1 (TRF1) and telomere repeat 
binding factor 2 (TRF2) proteins bind with double strand telomere DNA and are negative 
regulators of the length of the telomere.27 Telomere structure is characterized by a D-loop 
and T-loop which are formed by single strand 3´-end overhang intruding into telomere 
duplex DNA.28 This cap structure can stabilize and protect chromosome ends.28 The 
structure of telomere is demonstrated in Figure 3.  
Telomerase is an RNA-dependent DNA polymerase, composed of two essential subunits: 
the RNA template (hTER) and the catalytic subunit hTERT. Telomerase activity is silent 
in most human somatic cells because of the tight repression of hTERT expression. In up 
to 90% of human malignancies, telomerase is re-activated. Telomere length can be 
maintained by telomerase dependent and independent (alternative telomere-lengthening) 
mechanisms.29        
Telomerase RNA component 
Telomerase RNA template is essential for the enzyme activity of telomerase. 
Reconstituting telomerase RNA component hTER with hTERT can restore the telomerase 
activity in vitro.30 Unlike hTERT, hTER is expressed in most cell types including normal 
cells. hTERT mRNA expression level is often related to telomerase activity, for example 
in the case of gastric cancer.26 But hTER levels do not necessarily correlate with 
telomerase activity.  
1.3.2 Regulation of telomerase 
The expression and enzyme activity of telomerase is tightly regulated in normal somatic 
cells. Telomerase activity is controlled at different levels.29, 31, 32  
1.3.2.1 Regulation by transcription factors 
hTERT is, primarily, regulated at the transcriptional level. The transcription factor 
binding sites in the hTERT core promoter region include E-Box (5-CACGTG-3), GC-
Box (GGGCGG) and others.33, 34 C-Myc is one of the key regulators for hTERT 
transcription.33, 34 C-Myc forms heterodimers with Max and bind to the E-box activating 
downstream target genes such as hTERT. When Max forms heterodimer with Mad, it 
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antagonizes the role of c-Myc/Max complex and inhibits hTERT expression.35 
Transcription factor Sp1 is another positive regulator of telomerase; it can bind to the GC-
boxes on the hTERT promoter and regulate hTERT transcription.36 The core promoter of 
hTERT harbors at least five GC-boxes. Mutations in all five GC-boxes completely 
inhibited the hTERT promoter activity.37 p53 is an important suppressor of hTERT 
transcription.38 It was shown that the inhibition of telomerase activity by p53 requires the 
cooperation of transcription factor Specificity Protein 1 (Sp1).39, 40 Steroid hormones can 
regulate hTERT expression. Estrogen is the most well studied steroid hormone in the 
regulation of hTERT. Estrogen can directly trans-activate the hTERT gene, 41 or act 
through the AKT signaling cascade. 42 Estrogen deficiency can lead to inhibition of  
telomerase activity and shorter telomere lengths.43 
1.3.2.2 Regulation by epigenetic modifications 
 
In order to organize and package DNA in the nucleus, the DNA strand is wound around 
histones. There are five families of histone proteins, including H1/H5, H2A, H2B, H3 and 
H4. Modification of the histone tails can change chromatin conformation and regulate 
gene transcription. hTERT expression can be modified by different epigenetic 
mechanisms including acetylation, methylation, phosphorylation and ubiquitination.44 
Different enzymes such as histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) are implicated in the regulation of hTERT transcription.45 Histone acetylation 
and deacetylation change histone charges and accessibility of DNA with transcription 
factors. Histone deacetylation can repress hTERT transcription in normal human cells.46 
HDAC inhibitor trichostatin A can upregulate hTERT expression.47  Histone demethylase 
Retinoblastoma binding protein 2 (RBP2), by interacting with Mad1, is recruited to the 
hTERT promoter where it induces histone H3-K4 demethylation and thereby inhibits the 
transcription of hTERT.48 Ge et al. found that Mitogen activated protein kinase (MAPK)-
dependent phosphorylation of histone H3 is important in the induction of hTERT 
transcription and activation of telomerase.49  
1.4 ATPase Reptin            
 
Reptin is an AAA+ ATPase that belongs to the ATPase family associated with several 
cellular processes such as DNA replication and gene expression regulation.50 It is the 
mammalian homolog of DNA helicase RuvB which functions in the Holliday junction 
migration.51 Reptin is involved in the assembly and stability of telomere complex 
mediated by its ATPase activity.52 Using a TAP tag approach and mass spectrometric 
analysis, Reptin and Pontin were identified in the complex of telomerase. They were 
associated with telomerase in a cell cycle-dependent manner. Knocking down Reptin 
decreased telomerase activity.52 The physical association of Reptin with telomerase was 
also reported in budding yeast.53 When telomerase is not recruited to the telomere ends, 
Reptin still exists together with the telomere chromatin.53 
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Reptin often forms hexamers and dodecamers with Pontin, another member of AAA+ 
family of ATPases.54 There are controversial reports regarding the assembly of Reptin 
and Pontin. One study demonstrated that they were organized as dodecamers made from 
homo-hexamers of Reptin and Pontin.55 There was also a report showing that they exist as 
mixed hexamers.56  
Reptin and Pontin are overexpressed in some types of cancer.57, 58 For example, by 
comparing human hepatocellular carcinoma (HCC) tumor tissues with corresponding 
normal tissues, it was found that Reptin together with Pontin were overexpressed.58, 59 
Also Pontin was reported to be overexpressed in colon cancer.57 
                                            
 
Figure 4. Functions of Reptin. Reptin forms complex with Pontin and functions in telomerase 
assembly, chromatin remodeling, and cell survival and transcription regulation.  
The function of Reptin and Pontin can also be independent of their ATPase activity. They 
can act as transcription co-factors by interacting with transcription factors. The regulation 
of target genes by Reptin and Pontin can occur through two different mechanisms, 
transcriptional regulation and chromatin remodeling (Figure 4).  
1.4.1 Reptin/Pontin interact with different transcription factors                                         
Reptin and Pontin as the co-factors of c-Myc were shown in different models.60, 61 For 
example, Reptin and Pontin interact with Myc during the wing development of 
Drosophila. 60 Bellosta et al. reported that in drosophila d-Myc interacts with Reptin and 
Pontin in vitro. Reptin functions antagonistically with Pontin regarding the interaction 
with d-Myc. Also by interacting with Myc, Reptin regulates cell proliferation in the early 
development of Xenopus.61 Reptin and Pontin are required for the oncogenic 
transformation activity of c-Myc.62  Mutation of Pontin ATPase motif can inhibit the 
Chromatin remodeling  
Transcription co-factors  
Cell survival  
Telomerase assembly  
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transformation ability of c-Myc.  Reptin and Pontin can interact with transcription factors 
beta-catenin and tumor suppressor histidine triad protein (Hint1). 63, 64 Rottbauer et al. 
showed that Reptin and Pontin can regulate heart growth in zebrafish via the beta-catenin 
pathway.63  
1.4.2 Pontin/Reptin and epigenetic regulation 
 
Reptin and Pontin are subunits of different chromatin remodeling complexes, for example 
in yeast the INO80 remodeling complex65 and the TIP60 histone acetylase complex66. As 
chaperones they participate in the assembly of INO80 complex. 67 In the TIP60 complex, 
Reptin and Pontin are essential for the ATPase activity of the complex.66   
By recruiting different chromatin remodeling complexes, Reptin and Pontin can 
antagonistically regulate the expression of the tumor metastasis suppressor Kangai 1 
(KAI1). 68 In metastatic prostate cancer cells, Reptin and histone deacetylase HDAC were 
recruited together with beta-catenin to inhibit KAI1. In non-metastatic tumor cells, HAT 
Tip60 and Pontin chromatin remodeling complex were recruited to the KAI1 promoter.68 
Pontin can regulate the oncogenic properties of beta-catenin by chromatin remodeling.69 
Depletion of Pontin inhibited beta-catenin target gene expression. 69 Reptin and Pontin 
can regulate the process of nonsense-mediated mRNA decay which is involved in cancer 
development. 61, 70, 71 Reptin and Pontin are also implicated in the synthesis of small 
nucleolar RNAs (snoRNAs).72 
1.5 Senescence   
 
1.5.1 Introduction 
Cellular senescence is an irreversible cell growth arrest. Senescent cells remain viable and 
metabolically active, which distinguish them from dead cells. Senescence can be 
triggered by different stimuli such as DNA damage, telomere attrition, and oncogene 
activation. Senescence can be divided into three categories: premature senescence, 
replicative senescence and oncogene-induced senescence. Premature senescence is 
induced by stress signals such as DNA damage. Replicative senescence is triggered by the 
successively shortened telomeres. Oncogene-induced senescence is caused by aberrant 
activation of oncogenes, for example, overexpression of Ras can trigger senescence and 
block excessive proliferation. Because senescent cells cannot re-enter the cell cycle, it 
acts as a barrier for the immortalization and transformation of cells.  
Senescent cells can be identified by characteristic cell morphology with enlarged 
cytoplasm and can be positively stained for beta-galactosidase at pH6. Several cell cycle 
check point proteins are involved in and up-regulated during senescence, such as p53, 
p21cip1 and p16INK4a. Senescence is also associated with formation of senescence-
associated heterochromatic foci (SAHF).73             
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Figure 5. Types of senescence. Senescence can be induced by telomere attrition, DNA 
damage, and oncogene activation. 
 
1.5.2 Regulation of senescence 
Overexpression of oncogenes, for example Ras, can induce senescence to counteract the 
excessive pro-proliferation signals. INK family proteins p19ARF and p16Ink4a are 
implicated in mediating oncogene-induced senescence. Oncogene activation can activate 
p19ARF; whereas p19ARF inhibits mouse double minute 2 homolog (MDM2) which can 
inhibit p53 accumulation through proteasomal degradation. Oncogene activation can also 
activate p16Ink4a. p16Ink4a can inhibit cyclin-dependent kinase CDK4/6 and induce cell 
cycle arrest by regulating the tumor suppressor protein Rb. Hypophosphorylated Rb is at 
its active state, E2F target genes are silenced, and cells go to senescence.74 Rb can also 
mediate the formation of heterochromatin by methylation of histone H3 lysine 9 
(H3K9me) and induce senescence.74  
DNA damage-induced by chemotherapeutic drugs (e.g. etoposide) can cause DNA double 
strand break. p53 is activated and it in turn activates downstream p21cip1. DNA damage- 
induced senescence can also be mediated through p16Ink4a.75  
Replicative senescence is induced by progressive telomere shortening. Telomere attrition 
can cause chromosomal end to end fusions. These will be recognized as double-strand 
breaks and trigger the DNA damage repair machinery. P53-p21 and p16INK4a-Rb signaling 
are essential regulators in mediating replicative senescence. In many human tumors, cell 
cycle checkpoint proteins for example p53 and INK4 families are silenced by mutations 
or promoter methylation which compromise the senescence barrier. 
1.5.3 Role of senescence in cancer 
Senescence is an important suppression mechanism in the premalignant lesion step. In 
prostate cancer, cellular senescence induced by cell cycle check point protein p27kip1 up-
regulation was shown to be a barrier during the development from prostatic hyperplasia 
and prostatic intraepithelial neoplasia to invasive tumor.2 Senescence is an initial barrier 
during lymphoma development.76 Histone methyltransferase Suv39h1 is required for Rb 
mediated methylation of histone H3 lysine 9 and senescence associated heterochromatin 
DNA  damage 
Senescence 
Oncogenes 
Telomere attrition 
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formation.77 Braig et al. found that Eµ-N-Ras transgenic mice with Suv39h1 
heterozygous lesions developed lymphoma at a significantly earlier phase than N-Ras-
transgenic wild-type mice.  It was demonstrated that the senescence gatekeeper can delay 
the onset of oncogenic Ras-induced malignancy. 76 
However, senescence can also be an important cancer promoting mechanism. In response 
to anti-cancer drugs, senescence can lead to therapeutic resistance. Senescent cells resting 
in G1 cell cycle will be resistant to anti-cancer drugs targeting proliferating cells. 
Furthermore, senescent cells may form a favorable microenvironment for tumor 
progression.78 It was shown in the co-culture setting that senescent fibroblasts can 
promote the proliferation of prostate epithelial cells.78 Conditioned medium from the 
senescent fibroblasts also promotes the growth of prostate epithelial cells. The 
tumorigenic  effect  of senescent fibroblasts was postulated to be mediated by paracrine 
factors such as growth factors or inflammatory factors secreted by these growth-arrested 
fibroblasts.78  
1.6 Transcription factor FoxM1 
FoxM1 is member of the Forkhead transcription factor family. FoxM1 has three spliced 
isoforms: FoxM1a, FoxM1b, and FoxM1c. FoxM1b and FoxM1c are actively involved in 
regulating cellular proliferation. FoxM1 is expressed in embryonic tissues and 
proliferating cells but silent in terminally differentiated cells. In malignant cells, FoxM1 
expression is up-regulated. FoxM1 expression can be up-regulated by the oncogenes c-
Myc and Ras;79 whereas inhibited by tumor suppressors such as p53,80 and p1981. FoxM1-
induced anchorage-independent cell growth on soft agar can be inhibited by p19.81 
FoxM1 activates transcription factors c-Myc and c-Fos that promote cell proliferation. 
The target genes of FoxM1 also include cell cycle checkpoint proteins during G1-S 
transition,82 S phase progression,83 G2-M transition83 and M phase progression.84  
1.6.1 Role of FoxM1 in human cancer 
FoxM1 is deregulated in a variety of  human tumors, for example lung cancer,85 prostate 
cancer,86 glioblastoma,87 basal cell carcinomas.88 Elevated expression of FoxM1 is 
correlated with the degree of malignancy. Thus, in prostate adenocarcinomas, 86 cervical 
cancer, 89 glioblastoma, 87 and non-small cell lung cancers, 85 FoxM1 is expressed at 
higher levels at more advanced tumor stages.  
FoxM1 plays critical roles in the regulation of proliferation, tumorigenesis, angiogenesis, 
and invasion of tumor cells.83 The roles of FoxM1 in human cancers are illustrated in 
Figure 6. The growth promoting function of FoxM1 in cancer cells is described in 
different types of cancers, for example in both in vitro and in vivo models of prostate 
cancer86, and lung cancer.85 Depletion of FoxM1 in tumor cells, for example in prostate 
cancer cells,86 lung cancer cells85 and glioblastoma cells87 inhibits the anchorage-
independent growth of tumor cells on soft agar and impairs the tumor formation ability of 
cancer cells in nude mice.87  
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Figure 6. Roles of FoxM1 in human cancer. FoxM1 exerts its functions in cell cycle 
regulation, DNA damage repair, angiogenesis, invasion and migration, tumorigenesis, drug 
resistance and inhibition of senescence.  
In certain cancers, for example prostate cancer86 and lung adenocarcinomas90, FoxM1 
promotes tumor progression. FoxM1 overexpression promotes the metastasizing capacity 
of prostate cancer cells.91 In transgenic adenocarcinoma of the mouse prostate (TRAMP) 
and Lady transgenic mouse models of prostate cancer, overexpression of FoxM1 can 
accelerate the tumor development.86 In hepatocellular cancer cells, FoxM1 stimulates the 
expression of lysyl oxidase (LOX) and lysyl oxidase-like 2 (LOXL2) to prepare a pre-
metastatic niche for HCC cells.92 In glioma cells, FoxM1 promotes angiogenesis of tumor 
cells by up-regulating VEGF expression.93 Matrix metalloproteinase (MMP) can degrade 
basement membrane and extracellular matrix to facilitate the metastasis of tumor cells. In 
pancreatic cancer cells, FoxM1 enhances the invasion and angiogenesis of cancer cells by 
inducing the expression of matrix metalloproteinase 2 and 9 (MMP2 and MMP9).94 
Similar effects of FoxM1 on MMP2 were  reported in glioma cells.95  
FoxM1 is also implicated in the resistance of tumor cells to chemotherapy. For example, 
FoxM1 overexpressing breast cancer cells are more resistant to cisplatin, 96 and 
trastuzumab treatment97. FoxM1 induced trastuzumab resistance in breast cancer cells is 
associated with the trastuzumab induced up-regulation of p27kip. 97 It was also found that 
in gastric cancer cells, overexpression of FoxM1 can induce chemotherapeutic resistance 
of gastric cancer cells to docetaxel.98  
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1.6.2 Role of FoxM1 in cellular senescence 
FoxM1 is also implicated in regulating cellular senescence. FoxM1-/- mouse embryonic 
fibroblast cells undergo premature senescence during their early passages.82 This is 
mediated by the up-regulation of p27Kip1. FoxM1 regulates p27Kip1 expression through 
multiple mechanisms. FoxM1 stimulates the expression of SCF ubiquitin ligase complex 
subunit S-phase kinase-associated protein 2(Skp2) that mediates the ubiquitin proteasome 
degradation of p27Kip1.82, 99 FoxM1 also increases the nuclear export of p27Kip1 by 
regulating growth factor-induced expression of kinase-interacting stathmin (KIS).100 
Depletion of FoxM1 can induce the nucleus accumulation of p27Kip1. Consistently during 
pancreas development, depletion of FoxM1 increased the nuclear amount of p27Kip1 and 
induced senescence in pancreatic beta cells.  Oncogenic Ras can induce senescence by 
up-regulating ROS.101 The study by Park et al described that ROS enrichment induced by 
Ras increased the expression of FoxM1. 79 Depletion of FoxM1 leads to oxidative stress 
induced senescence. 79 It suggested that up-regulation of FoxM1 can be an adaptive 
machinery of cancer cells. Also FoxM1 was found to be a substrate for cyclin dependent 
kinases CDK4 and CDK6. Its phosphorylation by CDK4 and CDK6 prevents the onset of 
senescence.102   
FoxM1 is proposed as a potential target of cancer therapy. 103 Targeting FoxM1 can be 
restricted to cancer cells because FoxM1 is overexpressed in proliferating cells. There are 
studies reporting on potential inhibitors of FoxM1. Radhakrishnan et al. identified that 
antibiotic Siomycin A was a specific inhibitor of FoxM1.104 This thiazole antibiotic 
targets FoxM1 and thereby induces apoptosis in human cancer cells.105 The small 
molecule thiostrepton can inhibit the binding of FoxM1 to the promoter of its target 
genes.106 PPARγ agonists such as thiazolidinediones and proteasome inhibitors like 
bortezomib also inhibit the expression of FoxM1.107 
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1.7 Prostate cancer 
 
Figure 7. The Human prostate gland. It is mainly composed of epithelial cells, basal cells 
and stromal cells. 
1.7.1 Introduction 
The prostate gland’s physiological function is to produce secretory proteins e.g. prostate-
specific antigen (PSA) into the seminal fluid and facilitate the fertility of sperms. The 
prostate gland is divided into the peripheral zone, central zone and transition zone. The 
majority of prostate cancer derives from the prostate peripheral zone. Tumors arising 
from the central zone are relatively rare. Growth of prostate cells in the transition zone 
can cause benign prostatic enlargement and can also cause prostate cancer.  
Prostate cancer is the most frequent malignancy and second leading cause of cancer 
related deaths in men in industrialized countries. 12 Several factors are associated with an 
increased risk to develop prostate cancer. This type of cancer usually afflicts elderly men. 
Ethnicity is another risk factor.108 Thus, prostate cancer has a higher incidence in African-
American men compared to Asian men. Diet, smoking, obesity are also correlated with 
the occurrence of prostate cancer.108 Benign prostate hyperplasia is commonly observed 
in elderly men which can increase the probability of developing prostate cancer.109  
1.7.2 Molecular mechanisms of prostate cancer 
Androgens play an essential role in the development of normal prostate and in the 
development of prostate cancer. Androgen regulated signaling can be initiated by the 
binding of androgen ligand with androgen receptor (AR), a member of the steroid 
hormone receptor family. After binding with the ligand, ARs dissociate from heat shock 
proteins, translocate to the nucleus and bind with androgen response elements (AREs) in 
the promoter regions and  regulate the expression of target genes.110  
Epithelial cells 
Basal cells 
Basal membrane  
Stromal cells 
Human prostate 
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Prostate cancer can be divided into two types: castration sensitive prostate cancer and 
castration refractory prostate cancer. Castration refractory is common in the late stage of 
prostate cancer. Androgen withdrawal can cause apoptosis of hormone sensitive prostate 
normal cells and tumor cells at the early stage of prostate cancer. 
AR is an important promoter of prostate cancer development. Several mechanisms can 
induce over-activation of AR signaling: overexpression of the receptor due to gene 
amplification, ligand independent activation of AR, mutation of the receptor which can 
decrease the specificity of the ligand binding and AR activation by tyrosine kinases. 111 
Loss of expression of the tumor suppressor gene PTEN is found in 20-30% of metastatic 
prostate cancer.112 Loss of PTEN expression or activity in prostate cancer can occur by 
homozygous deletions, loss of heterozygosity and inactivating mutations. PTEN is an 
important negative regulator of PI3K-AKT signaling pathway by dephosphorylating 
phosphatidylinositol (3-5)-triphosphate (PIP3) to phosphatidylinositol 4, 5-bisphosphate 
(PIP2). Loss of PTEN leads to over-activation of PI3K-AKT signaling pathway. Prostate 
cancer cells with PTEN double allele mutation are resistant to hormone deprivation 
treatment.113 
TMPRSS2-ERG is a key factor in prostate cancer development. The genomic alteration 
of TMPRSS2-ERG is created by fusion of androgen-regulated gene TMPRSS2 with ETS 
transcription factors ETS-Related Gene (ERG), ETS translocation variant 1 (ETV1), or 
ETS translocation variant 4 (ETV4). It exists in 40 to 80% of prostate cancers and its 
expression level increases with higher prostate cancer stages.114 
1.7.3 Cancer associated fibroblasts in prostate cancer 
Prostate stroma cells are implicated in the normal development and differentiation of 
prostate cells. Prostate cancer stromal compartment is composed of different components 
including CAFs, immune cells, macrophages, pericytes, endothelial cells and extracellular 
matrix. CAFs are the most prominent component of tumor stroma.115  
CAFs are one of the major constituents of the tumor stroma.116, 117 The role of CAFs in 
prostate cancer development has been demonstrated and recapitulated by various co-
culture and recombination experiments.117 The reciprocal interaction between cancer 
associated fibroblasts and tumor epithelial cells can be mediated by paracrine factors 
growth factors, chemokine, cytokines and other mediators. 
Growth factors are the most well-known regulators of the interaction between tumor cells 
and tumor stroma. For example, HGF from fibroblast cells can bind with c-Met on tumor 
cells and promote metastasis of tumor cells.118 Chemokines secreted by the tumor stroma 
also play a role in cancer progression. Stromal cell-derived factor 1 (SDF-1) secreted by 
CAFs participates in recruiting endothelial progenitor cells to promote angiogenesis of 
breast cancer.119 SDFs secreted by CAFs bind with Chemokine (C-X-C motif) ligand 12 
(CXCL12) receptor on breast cancer cells and promote the growth of breast cancer cells 
by paracrine signals.119 The role of cytokines in tumor microenvironment is well 
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established. For example, Interleukin 6 (IL-6) derived from bone marrow stromal 
fibroblasts has been shown to promote the growth of prostate cancer cells.120  
The potential roles of CAFs in prostate cancer are illustrated in Figure 8; i) CAFs can 
promote the progression of prostate cancer cells from immortal phenotype to tumorigenic 
phenotype. In a co-culture study, Olumi et al. described that normal prostatic fibroblasts 
and CAFs exhibited different effect on initiated human prostatic epithelial cells which 
were transformed by simian virus 40 (SV40).121 Co-culturing of prostate epithelial cells 
with prostate CAFs led to the onset of prostatic intraepithelial neoplasia in the prostate 
epithelial cells. In contrast, the phenomenon was not observed when prostate cancer cells 
were co-cultured with normal prostate fibroblasts; ii) CAFs can promote the proliferation 
of prostate cancer cells. It was found that insulin-like growth factor-1(IGF-1) from 
prostate stroma can promote the growth of prostate cancer cells.122 Insulin-like growth 
factor-1 receptor (IGF-IR) abrogation on prostate epithelial cells stimulates Extracellular 
signal-regulated kinases (ERK) tyrosine kinase signaling and increase proliferation of 
prostate cancer cells;122 iii) CAFs can promote the occurrence of EMT and acquisition of 
stem cell-like characteristics in prostate cancer cells.123 In a study by Giannoni et al, it 
was found that the bi-directional interaction between prostate cancer cells and CAFs can 
stimulate EMT of tumor cells.123 Fibroblast cells secrete MMP which can facilitate EMT 
of cancer cells and contributes to the acquisition of stem cell-like characteristics in 
prostate cancer cells;123 iv) cancer cells need to acquire mobility to migrate to 
surrounding tissues. CAFs can promote this ability in prostate cancer cells. Augsten et al. 
demonstrated by co-culture experiments and an animal model that Chemokine (C-X-C 
motif) ligand 14 (CXCL14) secreted by prostate cancer associated fibroblast can promote 
the growth of prostate cancer xenografts, increased tumor angiogenesis and macrophage 
infiltration.124 
 
Figure 8. Roles of cancer associated fibroblast in prostate cancer. Through reciprocal 
crosstalk between prostate cancer cells and prostate tumor stroma, CAFs can regulate several 
hallmarks of prostate cancer including tumor proliferation, angiogenesis, EMT and acquisition of 
EMT Stemness Tumor  
growth 
Angiogenesis  
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stem cell traits. TGF-beta: transforming growth factor beta IL-6: Interleukin 6 CXCL14: 
Chemokine (C-X-C motif) ligand 14 MMP: matrix metalloproteinase. 
1.7.4 Stages and treatments of prostate cancer  
Prior to the initiation of prostate cancer treatment several factors have to be considered: 
disease´s stage, type of prostate cancer, patients´ overall health condition and life 
expectancy. The stage of prostate cancer is an important predictor of the patients´ 
response to therapy. The most commonly used method is Gleason score grading 
system.108 It is valued according to the prostate tissue morphology under the microscope. 
It comes from the sum of two scores. The first grade score is assigned to the most 
common tumor pattern under the microscope. The second grade score is assigned to the 
next most common tumor pattern. Gleason score is the sum of the two grades and it 
ranges from 2 to 10. Higher Gleason scores predict a worse prognosis.  
Treatment modalities of prostate cancer include “watchful” waiting, surgery, androgen 
deprivation therapy, radiotherapy, chemotherapy, cryo-therapy and palliative therapy. If 
the expected life span of the patients is less than 10 years, patients usually undergo 
watchful waiting. Surgical management including radical prostatectomy is performed in 
patients who are in good health condition. Prostate and nearby lymph nodes are removed 
during surgery. Androgen deprivation therapy can be conducted at the early stage and late 
stage of prostate cancer. Androgen deprivation can be achieved by chemical castration or 
surgical castration. Different factors in the androgen signaling axis can be targeted by 
hormone deprivation therapy. Luteinizing hormone-releasing hormone (LHRH) agonists 
can inhibit the production of testosterone by inhibiting the release of luteinizing 
hormone.125 Inhibitors of the enzyme 5-reductase can inhibit the testosterone conversion 
step. Androgen receptor can also be a direct therapeutic target. For example anti-androgen 
MDV310 is an AR antagonist.126 It can inhibit receptor ligand interaction by targeting 
receptor´ ligand binding domain. Deprivation of hormone induces apoptosis of prostate 
cancer cells. But most of patients will relapse after hormone deprivation therapy. 
Currently treatment for castration resistant prostate cancer patients is still a big challenge 
in the clinic. Mitoxantrone plus a glucocorticoid provide palliative benefit to the patients 
but does not improve the survival of the patients.127 Docetaxel which is the first 
chemotherapy drug that was approved for this indication can improve the median survival 
of hormone refractory metastatic prostate cancer patients.128 The improvement, however, 
is only 2.4 months with this regimen.128 Development of suitable therapeutic methods for 
castration-resistant prostate cancer are warranted.  
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1.8 Tyrosine kinase signaling  
1.8.1 Tyrosine kinases 
Tyrosine kinases are a family of kinases that can be categorized to receptor tyrosine 
kinases (RTK) and non-receptor tyrosine kinases (NRTKs). Vascular endothelial growth 
factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), endothelial 
growth factor receptor (EGFR) are some of the RTKs that promote tumor growth and 
metastasis. NRTKs also play a major role in tumor development and they include among 
others the Abl family (e.g. Abelson murine leukemia viral oncogene homolog 1(Abl)), the 
SRC family kinases (e.g. SRC, lymphocyte-specific protein tyrosine kinase (Lck), 
tyrosine-protein kinase Lyn (Lyn), tyrosine-protein kinase Fyn (Fyn)) and the JaK family 
(tyrosine kinase 2 (Tyk2), JaK1-3). Binding of ligands to the receptors on cellular 
membrane promotes receptor dimerization and auto-phosphorylation of the receptor 
intracellular spectrin homology (SH) domains. These domains act as docking sites for SH 
domain-containing proteins and recruit adaptor protein (e.g. growth factor receptor-bound 
protein 2 (GRB2), Son of Sevenless (SOS)) initiating a downstream signal transduction 
cascade that leads to the activation of several processes such as gene expression, 
proliferation and motility.  
1.8.2 Tyrosine kinase signaling in prostate cancer  
It was found that in both mouse prostate cancer models and clinical castration resistant 
prostate cancer samples tyrosine kinases are overexpressed or activated.129, 130 The main 
tyrosine kinase signaling cascades activated in prostate cancer are the Raf-Mitogen-
activated protein kinase/ERK kinase (MEK)-ERK, the PI3K-AKT and Janus kinase 
(JaK)-signal transducer and activator of transcription (STAT) signaling cascades (Figure 
9).129, 131 The Ras-Raf-MEK-ERK pathway provides mitogenic signaling to the cells and 
can regulate diverse biologic functions in the cells including apoptosis and cell cycle 
progression.132 The activation of the Raf-MEK-ERK pathway is important in the 
development of prostate cancer and correlates with higher Gleason score and poor 
prognosis of prostate cancer patients.133, 134 134 Signal transduction mutations in the Raf-
MEK-ERK pathway is not common in prostate cancer. It is postulated that the activation 
of this mitogenic signaling in prostate cancer can be due to the aberrant activation of 
upstream factors such as the deregulated RTK and NRTK.132, 135 
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Figure 9. Tyrosine kinase signaling cascades. Ras-Raf-MEK-ERK, the PI3K-AKT and 
JAK-STAT signaling cascades are the main downstream signaling cascades activated by 
tyrosine kinases in prostate cancer. 
In prostate cancer, the PI3K-AKT pathway promotes the growth,136 invasion137 and 
angiogenesis138 of prostate cancer cells. In 30-50% of prostate cancers the PI3K-AKT 
pathway is activated primarily due to PTEN silencing or aberrant activation of upstream 
RTKs.139, 140 It can confer cell death resistance to cancer cells by inhibiting the apoptotic 
activity of caspase 9 and Bad. mTOR is a downstream target of the PI3K-AKT pathway. 
It can induce phosphorylation of ribosomal p70S6K and eukaryotic initiation factor-4E 
binding protein (4E-BP) to initiate protein synthesis. Activation of PI3K signaling can 
also inhibit glycogen synthase kinase 3(GSK3) which can mediate stabilization and 
nuclear translocation of beta-catenin and induction of downstream target genes such as 
cyclin D and c-Myc.  
There is also an extensive cross-talk between the Raf-MEK-ERK pathway and PI3K- 
AKT. PI3K kinase can be directly activated by Ras.141 Conversely, over-activation of 
AKT signaling can lead to phosphorylation and inhibition of Raf.142  
Aberrant activation of tyrosine kinases can confer androgen-independent growth signals 
to prostate cancer cells. Tyrosine kinase phosphorylation can enhance transcription and 
nuclear translocation of the AR.143 The RTK insulin growth factor receptor (IGFR) and 
the NRTK SRC phosphorylate the AR, induce its nuclear translocation and thereby 
promote androgen-independent growth of prostate cancer cells.144 Androgen receptor 
signaling is also regulated by the MAPK signaling pathway and usage of MEK inhibitors 
impairs androgen receptor signaling.145 The PI3K-AKT pathway is involved in the 
progression from hormone sensitive to hormone refractory prostate cancer supported by 
evidence from both clinical and cell line data.146, 147  
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1.8.3 Tyrosine kinase inhibitor sorafenib  
Sorafenib (BAY43-9006, Nexavar), is a multi-tyrosine kinase inhibitor that can target the 
RTKs VEGFR, PDGFR-β and EGFR as well as NRTK such as Src.148 Sorafenib is a type 
II tyrosine kinase inhibitors, i.e. its inhibitory activity does not rely on the active 
conformation of the receptors.  
Sorafenib can exert its function by several mechanisms. Firstly, it can induce apoptosis in 
tumor cells. The apoptosis induction by sorafenib can be primarily mediated by down-
regulation of anti-apoptotic member of the Bcl-2 family Mcl-1 through translational 
inhibition.149-151 It can also be mediated by inhibition of the mitogenic signaling through 
targeting Raf.149 The Raf-MEK-ERK signaling pathway is the main target of sorafenib.148 
The inhibitions of MAP kinases by sorafenib and apoptosis induction were shown in 
different cancer cells including prostate cancer,152 hepatocellular carcinoma,153 breast 
cancer,148colon cancer 148 and multiple myeloma150. The induction of tumor cell apoptosis 
in different tumor models by sorafenib was established, including in PLC/PRF/5 HCC 
xenografts model153, MDA-MB-231 breast cancer model148 and multiple myeloma150. 
Secondly, sorafenib can inhibit tumor angiogenesis by targeting VEGFR, PDGFR-β 
tyrosine kinase signaling in renal cell carcinoma,154 melanoma xenograft.155 Sorafenib is 
approved by the U.S. Food and Drug Administration and the European Medicines Agency 
for the treatment of renal cell carcinoma and hepatocellular carcinoma. With regard to 
prostate cancer, there are several clinical trials using sorafenib in the treatment of 
castration resistant prostate cancer.156-158  
The molecular mechanisms of sorafenib-induced cell death in prostate cancer are not 
clearly elucidated in the prostate cancer setting. We have previously shown that sorafenib 
can induce apoptosis and autophagy in prostate cancer cell lines,152 but the molecular 
targets of sorafenib in prostate cancer are not known. 
                                         
Figure 10. Mechanisms of sorafenib. Sorafenib can exert its function by inducing apoptosis 
through Mcl-1 inhibition and induction of autophagy. 
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1.8.4 Resistance to tyrosine kinase inhibitor  
Resistance to TKIs is a big challenge that needs to be overcome in tumor therapy.159-161 
Several mechanisms can lead to the acquisition of resistance to tyrosine kinase inhibitors. 
Mutations on the TKI binding site in tyrosine kinase are the most frequent cause of 
resistance to TKIs. One amino acid residue mutation in ATP binding sites of tyrosine 
kinase receptor can cause the loss of binding of the TKI to the receptor. For example, a 
T674I mutation was reported to cause imatinib resistance.162 Protective signals from the 
microenvironment or overexpression of anti-apoptotic members can also cause resistance 
to TKIs.  Combination of TKIs with chemotherapy might overcome the drug resistance to 
a certain extent and increase treatment efficiency.  
1.9 Cell death 
1.9.1 Caspase-dependent cell death 
 
Caspase-dependent cell death mainly refers to the type I programmed cell death, 
apoptosis. Apoptosis plays important roles during embryonic development and is 
involved in the balance regulation between cell death and cell proliferation. Caspase-
dependent cell death can be divided into two categories, the extrinsic and intrinsic cell 
death pathway (Figure 11). The extrinsic pathway is mediated by the binding of tumor 
necrosis factor (TNF) or Fas ligand to their death receptors tumor necrosis factor receptor 
(TNFR) and Fas receptor. After binding with the ligands, intracellular death domain of 
the receptor recruits TNF receptor-associated death domain and Fas-associated death 
domain to form death-inducing signaling complex (DISC) which will activate the apical 
pro-caspase 8. Caspase 8 activation leads to the activation of the downstream effector 
caspases -3, -6 and -7. 
 
Figure 11. The apoptotic signaling cascades. Apoptosis can be executed by the extrinsic 
pathway and the intrinsic pathway. 
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The intrinsic cell death pathway is mediated by the mitochondria. It can be triggered by 
cell death stimuli such as DNA damage, chemotherapeutic drug treatment, ionizing 
radiation, Adenosine triphosphate (ATP) depletion and growth factor withdrawal. Upon 
activation, the pro-apoptotic Bcl-2 family members Bax and Bak translocate from the 
cytoplasm to the mitochondria to form pores on the outer mitochondrial membrane and 
cause mitochondrial membrane permeabilization.163 Cytochrome c is released from the 
inner mitochondrial membrane into the cytoplasm which is an important hallmark of 
apoptosis. Cytochrome c together with apoptotic protease activating factor 1 (Apaf-1) and 
pro-caspase 9 forms the "apoptosome", which main function is the activation of caspase-9. 
Capase-9 in turn activates the downstream effector caspase-3, -6 and -7.  
The apoptotic machinery is regulated by the Bcl-2 family proteins. There are three groups 
of Bcl-2 family members: the pro-apoptotic members, the anti-apoptotic members and the 
BH3-only proteins. Bcl-2, Mcl-1, Bcl-xL are the main members of anti-apoptotic Bcl-2 
family. Anti-apoptotic Bcl-2 members form complexes with the pro-apoptotic Bcl-2 
members such as Bak and Bax to inhibit their activation. The BH3-only proteins (Bid, 
Bim, Bad, Noxa, and Puma) can competitively bind with anti-apoptotic Bcl-2 members 
through their BH3 domain and release the pro-apoptotic Bcl-2 members to induce 
apoptosis. BH3 only protein Bim have three splice variants: Bim S, Bim L, and Bim EL. 
164 Bim S is the most potent one in inducing cell death.164 Bim can be regulated by 
Forkhead box O (FOXO) transcription factor which is downstream substrate of PI3K-
AKT signaling pathway. Bad can be phosphorylated at serine residues 112 and 136.165 
Phosphorylated Bad is sequestered by the signal transducer protein 14-3-3 and cannot 
activate apoptosis. The PI3K-AKT and the Raf-MEK-ERK pathways have been shown to 
induce the phosphorylation of Bad.165  
1.9.2 Caspase-independent cell death  
There are different modes of caspase-independent cell death. 166 They include the 
apoptosis inducing factor (AIF) mediated caspase-independent cell death, autophagy and 
mitotic catastrophe. Caspase-independent cell death is characterized by cell demise in the 
absence of caspase activation. AIF is a key factor in caspase-independent cell death.167 
AIF is in the inner mitochondrial membrane space under normal conditions. In the 
presence of cell death signals, AIF undergoes proteolytic cleavage and translocates from 
mitochondria to the nucleus where it causes large scale DNA fragmentation through 
endonuclease G. 167 AIF mediated caspase-independent cell death cannot be inhibited by 
the pan-caspase inhibitor Z-VAD.  
1.9.2.1 Autophagy 
There are three types of autophagy: macroautophagy, microautophagy and chaperone-
mediated autophagy. "Macroautophagy" will be referred to as "autophagy" in this thesis. 
Autophagy is an evolutionarily conserved mechanism for cells to maintain homeostasis. 
Autophagy can be triggered by different stimuli: nutrient starvation, cytotoxic drug and 
metabolic stress. Autophagy has two important functions. One is the degradation of 
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protein aggregates and organelles. Another function of autophagy is the recycling of 
nutrients. When cells are confronted with metabolic stress, cytoplasmic components such 
as ribosomes and mitochondria can be degraded to amino acids and fatty acids. These 
metabolites can be re-used in the synthesis of proteins and lipids.  
The process of autophagy occurs in four phases: nucleation, elongation, fusion and 
degradation. After initiation of autophagy, proteins and organelles are sequestered by the 
phagophore at the phagophore assembly site (PAS). Elongation and closure of 
phagophore leads to the formation of the autophagosome. Fusion of the autophagosomal 
outer membranes with lysosomes gives rise to the autophagolysosomes. Engulfed 
proteins and cellular organelles are degraded by proteases in lysosomes. The process of 
autophagy is demonstrated in Figure 12B. The process of autophagy is executed by 
several evolutionarily conserved proteins complexes. Autophagy initiation is regulated by 
two protein complexes: mammalian homolog of yeast Atg1 (ULK1) protein complex and 
Class III PI3K protein complex (Figure 12A). Members of the ULK1 protein complex 
include ULK1, ATG13, and focal adhesion kinase family interacting protein of 200 kD 
(FIP200). The ULK1 kinase complex plays an essential role in autophagy initiation. 
Members of class III PI3K protein complex include Coiled-coil myosin-like BCL2-
interacting protein (Beclin1) and Vps34. Beclin1 is a key regulator of autophagy. 168 For 
example, AKT can inhibit the initiation of autophagy by phosphorylation of Beclin1.168 
Lipidation of microtubule-associated protein 1A/1B-light chain 3 (LC3) is an important 
step in the elongation phase of autophagy (Figure12C). Two ubiquitin like protein 
conjugation systems ATG5-ATG7-ATG12 and LC3 are involved in the autophagosome 
formation phase. LC3 is firstly cleaved on c-terminal by ATG4 protease to form the 
cytoplasmic soluble LC3-I. LC3-I is conjugated with phosphatidyl ethanolamine (PE) and 
form LC3-phosphatidyl ethanolamine conjugate (LC3-II), a reaction that is catalyzed by 
the E1 ubiquitin enzyme like protein ATG7. ATG5 is a key regulator of LC3 lipidation. 
ATG12 is conjugated to ATG5 by E2 ubiquitin like protein Atg10. ATG5-ATG12 further 
forms a high molecular weight complex with ATG16. ATG5-ATG12-ATG16 facilitates 
the binding of LC3-PE to the autophagosome membrane.169 P62 (sequestosome 1 
(SQSTM1)) is an adaptor protein in the autophagy process. It has both ubiquitin binding 
and LC3 binding domains. By binding to both ubiquitinated proteins and LC3, it can 
transport the cargo into autophagosomes for degradation. If autophagy is impaired, p62 
cannot be degraded and accumulated in the cytoplasm. This will lead to DNA damage by 
induced oxidative stress which can promote tumorigenesis.170  
Finally in the late stage of autophagy, autophagosome fuses with lysosomes. The contents 
of the autophagosome are degraded by acidic hydrolases in lysosome. Lysosome-
associated membrane protein 2 (LAMP-2),  an integral  lysosome membrane protein, is 
essential for the autophagolysosome formation.171 In LAMP-2 knockout mice, 
autophagolysosome formation is impaired. 171 Defect of the late stage autophagy leads to 
the accumulation of autophagosomes.  
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Figure 12. Process of autophagy. A. initiation phase of autophagy B. autophagy process  
C. LC3 lipidation process. 
 
1.9.2.2 Regulation of Autophagy 
 
1.9.2.2.1 Autophagy regulation by PI3K-AKT-mTOR signaling 
PI3K-AKT-mTOR signaling is the major regulatory pathway of autophagy.172 Growth 
factors and nutrient conditions regulate the initiation of autophagy via the PI3K-AKT-
mTOR signaling pathway. Under nutrient rich condition, PI3K gets activated and 
phosphorylates AKT which in turn phosphorylates and inhibits tuberous sclerosis protein 
2 (TSC2). In the absence of activated TSC2, Ras homolog enriched in brain (RheB) is 
phosphorylated and activated which in turn will activate mTOR. mTOR inhibits the 
initiation of autophagy by phosphorylating and repressing ULK1. Under harsh metabolic 
C. 
A. 
B. 
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conditions (e.g. starvation, hypoxia) PI3K-mTOR pathway is inhibited, allowing for the 
autophagic machinery to be activated. 173 It was recently found that AKT can directly 
phosphorylate Beclin1 independently of mTOR thereby inhibiting autophagy and 
promoting oncogenesis.168 
1.9.2.2.2 Regulation of autophagy by metabolic stress 
Autophagy can be triggered by metabolic stress which is frequently observed in cancer 
cells. The initiation of autophagy process is regulated by 5' AMP-activated protein kinase 
(AMPK), an energy sensor in the cells. AMPK is a serine tyrosine kinase which can sense 
the level of adenosine monophosphate (AMP) and ATP. Increased AMP: ATP ratio can 
trigger the activation of AMPK by the serine threonine kinase liver kinase B1 (LKB1). 
Activated AMPK phosphorylates and inhibits mTOR thus allowing for the initiation of 
autophagy.  
1.9.2.2.3 Connection between apoptosis and autophagy 
There is an extensive cross-talk between apoptosis and autophagy. One convergence point 
is Beclin1.174 Beclin1 has a BH3-only protein domain which can bind with anti-apoptotic 
Bcl-2 family members.175 Bcl-2 binds with Beclin-1 and inhibits autophagy. It was shown 
that inhibition of Bcl-2 expression by small interfering RNA in MCF-7 breast cancer cells 
lead to autophagic cell death.176 ABT737,  a BH3 mimetic, can induce autophagy because 
it can interrupt the complex between Bcl-2 and Beclin1.177 Another convergence point is 
ATG5. 178 It is reported that ATG5 can be cleaved by calpains to a 24kD fragment which 
then acts as BH3-only protein interacting with Bcl-xL, allowing for the activation of Bax 
and the induction of apoptosis.178  
1.9.3 Autophagy in cancer and chemotherapy  
The role of autophagy in cancer is complex and context-dependent.179 Autophagy has a 
tumor suppressive role in the early stages of tumor development. Beclin1 is a 
haploinsufficient tumor suppressor gene. In mice carrying Beclin1 monoallelic deletion, 
the potential of tumor development was increased.175, 180  Furthermore, ~50% of human 
breast and prostate cancers patients have monoallelic deletion of Beclin1.181, 182 One 
explanation for the tumor suppressive function of autophagy is that defective autophagy 
can lead to the accumulation of damaged organelles such as mitochondria, accumulation 
of  ROS production and increased genomic instability.183 The degradation of p62 by 
autophagy is another explanation for tumor suppressive role of autophagy.170, 184 In 
autophagy defective tumors cells, p62 cannot be degraded and accumulates in the cells. 
Accumulation of p62 induces ROS which leads to DNA damage and tumorigenesis. 
Autophagy also plays tumor promoting roles since it is a survival mechanism for cells. 
Autophagy can protect cancer cells from metabolic, oxidative stress or cellular damage 
induced by different stimuli such as hypoxia, starvation and anti-cancer drugs.  Inhibition 
of autophagy can sensitize cancer cells to anti-cancer drug. LnCaP prostate cancer cells 
can utilize autophagy to survive from androgen deprivation treatment.185 In breast cancer, 
inhibition of autophagy can reverse the resistance of tumor cells to tamoxifen treatment. 
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186 Thus autophagy may also be a therapeutic target in the late stages of tumorigenesis.187  
The autophagy inhibitor chloroquine in combination with the TKI imatinib mesylate has 
shown better therapeutic efficiency in chronic myeloid leukemia both in vitro 
experiments and in clinic.188 In prostate cancer, TKIs together with autophagy modulators 
emerge as a potential treatment strategy.189 
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2. Aims of the studies 
The overall objective of the present study is to gain insights into the mechanisms of 
malignant transformation and mechanisms of drug-induced cell death, thereby contributing 
to a better understanding of oncogenic processes and the rational development of novel 
anti-cancer strategies. Specifically, the project is designed: 
1. To define potential roles for transcription factor FoxM1 in regulating telomerase 
and senescence of gastric cancer cells. 
2. To determine whether dysregulation of Reptin contributes to telomerase activation 
in these cancers. 
3. To delineate the mechanisms of sorafenib-induced cell death in prostate cancer. 
4. To examine the role of autophagy in prostate cancer response to therapy. 
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3. Results and discussion 
3.1 Paper I 
Reptin is overexpressed in gastric cancer and can regulate hTERT 
transcription 
In order to assess the expression of Reptin in gastric cancer, Reptin expression was 
examined in clinical gastric cancer patient samples by immunohistochemistry and reverse 
transcriptase (RT)-polymerase chain reaction (PCR). Expression of Reptin in primary 
gastric cancer tissues was significantly higher compared to that in normal gastric tissues. 
The expression of Reptin and hTERT was in parallel with each other in clinical samples. 
The expression of Reptin was also detectable in a series of gastric cancer cell lines (AGS, 
BGC, HGC, and KATO-III).  
In order to find out the role of Reptin in the pathogenesis of gastric cancer, Reptin was 
depleted by using a specific siRNA. Depletion of Reptin led to down-regulation of 
hTERT expression at the RNA level. Telomerase activity was also inhibited. Combined 
inhibition of Reptin and Pontin had synergistic inhibitory effect on hTERT mRNA level. 
However, Reptin and Pontin had an opposite effect on the hTERT promoter activity. 
Reptin can positively while Pontin negatively regulate the promoter activity. Studies have 
shown that Reptin and Pontin can have antagonistic regulation of target genes.63, 190 It was 
also shown that overexpression of one of them can lead to down-regulation of the other 
one's protein level.191 The antagonistic regulation by Reptin and Pontin could be a 
feedback loop that can regulate the target gene expression at a balanced level. 
It was found that depletion of Reptin leads to the co-depletion of Pontin. This is in line 
with previous findings which indicated that the stability of Reptin and Pontin relies on 
each other.52, 58 The co-depletion of Reptin and Pontin was also observed in human liver 
cancer cell line HepG2, breast cancer cells MCF7, prostatic cancer cells LnCaP and 
cervical cancer HeLa cells. 58 Silencing of Reptin by using siRNA did not change the 
Pontin mRNA level. 58   
In the current study, it was shown that inhibition of Reptin expression impaired the 
colony formation ability of gastric cancer cells. It was reported that silencing Reptin in 
vivo induced replicative senescence in human hepatocellular carcinoma in mice and 
inhibited the growth of explanted tumors. 192 Similarly, in renal cell carcinoma, depletion 
of Reptin can impair the clonogenic potential of renal carcinoma cells. Senescence was 
observed in the Reptin depleted renal cancer cells.193 The growth inhibition role of Reptin 
could be partially explained by the down-regulation of telomerase, since telomerase is 
critical in sustaining proliferation. This was also consistent with the finding that Reptin is 
subunit of telomerase complex and required for its activity.52 It was also reported that 
shRNA mediated depletion of p400 or knock down of p400 complex components Reptin 
and Pontin can induce senescence in primary human diploid fibroblasts as shown by 
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SAHF formation and senescent β-gal staining.194 This report gives another explanation of 
the senescence induction by Reptin inhibition. 
The hTERT promoter-luciferase reporter is a commonly used tool for study of telomerase 
transcription regulation. By this assay it was found that hTERT promoter activity was 
regulated by Reptin and the hTERT transcription needed the cooperation between c-Myc 
and Reptin. When the c-Myc binding cassette, E-box, was absent from the hTERT 
promoter region, regulation of hTERT by Reptin was attenuated. By performing 
immunoprecipitation experiments, we also confirmed the interaction of Reptin with c-
Myc in gastric cancer cells. C-Myc is one of the key regulators of hTERT transcription. 
But E-box (5´-CACGTG) is not a specific binding site for c-Myc. It can also be bound by 
other transcription factors. It would be possible to confirm the specificity of c-Myc 
dependence in the regulation of hTERT by Reptin. There was a study showing that c-Myc 
N-terminus was responsible for the recruitment of Reptin and Pontin on their target gene 
promoters.62 To approach this issue, c-Myc N-terminus can be genetically mutated and 
the effect examined. 
Main findings in Study I: 
1. Reptin is over-expressed in primary gastric cancer samples. 
2. Reptin is required for the transcription of the hTERT gene. 
3. hTERT transcription regulation by Reptin requires its cooperation with c-MYC. 
3.2 Paper II 
FoxM1 is overexpressed in gastric cancer and its inhibition leads to 
senescence  
Extensive studies from both human tumor cell lines and patients´ samples establish that 
FoxM1 is aberrantly activated in most human malignancies. Our study provided evidence 
that FoxM1 is overexpressed in gastric cancer. FoxM1 was significantly overexpressed in 
gastric cancer patient’s samples examined by immunohistochemistry and RT-PCR and 
also in gastric cancer cell lines (AGS, BGC-823, HGC-27 and KATO-III). Similar results 
was repeated by another group showing that FoxM1b, one isoform of FoxM1, was 
expressed at significantly higher levels in the patients’ samples from gastric tumors and 
lymph node metastatic sites. It was also demonstrated that in the FoxM1 overexpressed 
animal model, FoxM1 can promote the growth and metastasis of gastric cancer cells.195 
We found that siRNA mediated knockdown of FoxM1 induced senescence in gastric 
cancer cells and led to a diminished clonogenic potential. This is consistent with previous 
findings that knockdown of FoxM1 impaired the tumorigenesis of malignant cells.85, 87 
P53-p21Cip1 and p16ink4a-Rb signals regulating senescence were not affected by FoxM1 
depletion. In all four tested cell lines, there were no differences in p21Cip1 expression level 
before and after knocking down of FoxM1. In contrast, p27kip level was increased in all 
four cell lines. To verify the role of p27kip in the senescence induction, p27kip siRNA was 
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transfected into the gastric cancer cells. Deceased p27kip expression attenuated the effect 
of FoxM1 depletion. It further proves the regulatory axis that FoxM1 regulates Skp2 and 
Cyclin-dependent kinase activating kinase1 (Cks1) expression, 82 Skp2 as the upstream 
regulator of p27kip can mediate the ubiquitin proteasome degradation of p27kip. FoxM1 
depletion inhibits Skp2 and induces the accumulation of p27kip. 82 
P27kip mediated senescence was reported in previous studies.196 p27Kip1 can be regulated 
by PTEN/PI3K-AKT signaling which is implicated in the carcinogenesis of many 
malignancies. Inhibition of PI3K-AKT signaling or overexpression of PTEN can increase 
the expression level of p27Kip1.197 It was shown that p27Kip1 was a direct inducer of p53-
independent senescence in mouse embryonic fibroblasts that did not express the 
suppressor VHL (von Hippel-Lindau).198 The p53-independent p27Kip1 mediated 
senescence regulation is also supported by another study showing that Skp2 inactivation 
induced senescence via Activating transcription factor 4(Atf4), p27Kip1 and p21Cip1 but 
independent of p53.199 
hTERT is important for senescence prevention by maintaining telomere length in cancer 
cells. We examined the effect of FoxM1 depletion on expression of hTERT, and found in 
FoxM1-depleted gastric cancer cells that hTERT expression and telomerase activities 
were down regulated.  
Main findings in Study II: 
1. FoxM1 was up-regulated in gastric cancer cell lines and primary gastric cancer. 
2. Depletion of FoxM1 induces senescence in gastric cancer cells.  
3. Senescence triggered by FoxM1 inhibition is p53-and p16-independent and mediated 
by the enhanced expression of p27kip1. 
4. Depletion of FoxM1 inhibits the expression of c-Myc and hTERT. 
3.3 Paper III 
 Sorafenib induced prostate cell death by different mechanisms  
Tyrosine kinase inhibitors are attracting more and more attention as potential therapeutic 
strategies against prostate cancer. Sorafenib can target multiple tyrosine kinase signalling 
cascades and therefore could be a good candidate. We have previously shown that 
sorafenib can induce cell death in prostate cancer cell lines.152 In this study, we delineated 
the mechanisms of sorafenib-induced cell death in two model prostate cancer cell lines. 
22RV1 cells, a hormone sensitive, non-metastatic prostate cancer cell line, was more 
sensitive to sorafenib and displayed faster cell death kinetics comparing to PC3 cells, a 
hormone refractory, metastatic prostate cancer cell line. We found that the different 
cytotoxic efficacy of sorafenib is due to the different signalling cascades targeted by 
sorafenib. In 22RV1 cells, the constitutively active Raf-MEK-ERK pathway was 
inhibited by sorafenib whereas in PC3 cells this pathway was not activated. In PC3 cells, 
the PI3K-AKT pathway was constitutively active and the cytotoxic activity of sorafenib 
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was mediated by inhibiting this pathway. In a recently published study it was also shown 
that sorafenib can induce cell death in PC3 and 22RV1 cells.200 Their experiments 
indicate that the differential cell killing effect of sorafenib might be due to the differential 
expression of AR which can be inhibited by sorafenib treatment. 200  
Mcl-1 down regulation is an important mechanism of sorafenib-induced apoptosis. We 
found in this study that overexpression of Mcl-1 in prostate cancer cells protected them 
from sorafenib-induced cell death. Mcl-1 down-regulation potentiated prostate cancer 
cells to sorafenib treatment which is independent of Raf-MEK-ERK and PI3K-AKT 
signaling pathways. The subsequent study from Oh et al. also showed that the down 
regulation of Mcl-1 and inhibition of AKT signaling in sorafenib-induced apoptosis in 
prostate cancer cells.200 
In the current study, it was also found that protective autophagy was induced in these 
prostate cancer cells. This is in line with one reported role of autophagy in chemotherapy, 
as an adaptive mechanism to protect cancer cells from chemotherapy. CAFs play 
multifaceted roles in the prostate cancer pathogenesis.121, 124 It was found in study III that 
CAFs can protect 22RV1 and PC3 prostate cancer cells from sorafenib-induced cell death. 
This protection can be reversed by the combination treatment of sorafenib with ABT373.  
Main findings in Study III: 
1. Sorafenib induces apoptosis in two prostate cancer cells, 22Rv1 and PC3, with 22RV1 
being more sensitive of the two. 
2. Targeting of distinct signaling cascades in 22Rv1 and PC3 defines the efficacy of 
sorafenib. 
3. In both PC3 and 22Rv1 cells, Mcl-1 depletion is required for the induction of cell death 
by sorafenib. 
4. Primary CAFs protect the cancer cells from sorafenib-induced cell death, and this 
protection could be largely overcome by co-administration of the Bcl-2 antagonist 
ABT737. 
3.4 Paper IV 
ATG5 independent cytotoxic autophagy was found in prostate cancer 
cell  
In this study we found that treatment with sorafenib-induced mitochondria depolarization 
and caspase-independent cell death in DU145 cells. Treatment with and early inhibitor (3-
methyladenine (3-MA)) and a late inhibitor of autophagy (chloroquine) increased the 
amount of cells with dissipated mitochondria. Inhibition of autophagy initiation by using 
shRNA against Beclin1 and the early stage autophagy inhibitor 3-MA protected DU145 
cells from sorafenib-induced cell death. Surprisingly, LC3 lipidation was not evident in 
DU145 cells due to the lack of ATG5 expression. Restoration of ATG5 expression 
partially re-constituted LC3 lipidation and partially rescued DU145 cells from sorafenib-
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induced cell death. ATG5 lack of expression was found in 18% of prostate cancer patient 
samples. We speculated that autophagy was initiated to remove the damaged 
mitochondria, sustain the ATP level and the metabolic homeostasis of the cells. 
Surprisingly, autophagosome formation occurred in an ATG5-independent manner in 
sorafenib treated DU145 cells. Similar results were reported in etoposide induced ATG5 
independent autophagy in MEFs cells.201 Non-canonical Beclin1-independent autophagy 
was also observed in resveratrol-treated human breast cancer cells.202It was recently 
shown that alternative splicing of ATG5 may be the reason for the loss of ATG5 
expression in DU145 cells.201 
We found that manipulation of autophagy key regulators such as Ulk1 and Beclin1 can 
attenuate cell death induced by sorafenib. Further investigations are needed to describe 
the regulation of the non-canonical autophagy process. It is unknown if prostate cancer 
cells acquire another mode of autophagy for example chaperone-mediated autophagy to 
regulate the protein turn over while macroautophagy is defective. In MEFs, mitochondria 
and proteins were degraded during the ATG5-independent autophagy.201   
In the current study we found that overexpression of PI3K-AKT signaling pathways 
suppressed the cytotoxic autophagy and led to the resistance of sorafenib in DU145 cells. 
The resistance to sorafenib can be reversed by the PI3K-inhibitor LY294002. Comparing 
to Raf/MEK/ERK pathway, PI3K-AKT signaling is more likely implicated in drug 
resistance of prostate cancer cells and is more promising for the targeted therapy. In 
prostate cancer patients, loss expression of ATG5 also exists. The loss expression of 
ATG5 has not been reported in prostate cancer patients before. It is warranted to know the 
mechanism of ATG5 loss in the patient samples. It was shown that  in mice with ATG5 or 
ATG7 depletion,  mice developed tumors in the liver.203 It is interesting to know whether 
ATG5 loss of expression is correlated with tumorigenesis in prostate cancer patients. 
Main findings in Study IV: 
1. DU145 cells undergo autophagic cell death in response to sorafenib. 
2. Loss expression of ATG5 is responsible for the cytotoxic autophagy. 
3. Development of resistance to sorafenib is associated with the activation of the 
constitutive of the PI3K-AKT pathway and subsequent inhibition of this cytotoxic 
autophagy  
4. Tissue microarray analysis revealed that 18% of prostate cancer patients do not 
express ATG5. 
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4. Future perspectives  
4.1 Exploring the regulators of Reptin and targeting Reptin as 
therapeutic strategy 
In study I, we showed that Reptin was overexpressed in gastric cancer and it was required 
for hTERT transcription. Inhibition of Reptin impaired the clonogenic potential of gastric 
cancer cells. These findings provide a rationale for targeting Reptin to treat gastric cancer.  
Understanding the regulation and function of Reptin will provide us further choices in 
gastric cancer treatment. The upstream regulators for Reptin are poorly characterized. The 
mechanism of the up-regulation of Reptin and Pontin in cancer is an unknown question to 
answer. Gene amplification can be a possible reason. Pontin maps to chromosome 3q21 
which is a hot spot for amplification in non-small cell lung cancer.204 In gastric cancer, 
high level of amplification at chromosome 3q21 was also reported.205 Reptin can also be 
regulated by epigenetic machinery. For example, Reptin can be modified by sumoylation 
in metastatic prostate cancer cells. Sumoylation of Reptin had a negative effect on tumor 
suppressor KAI1 expression and further regulated the metastasis potential of prostate 
cancer cells.206 Reptin can also be modified by methylation. Methylated Reptin can 
suppress the expression of hypoxia-dependent target genes which was mediated by the 
transcription factor HIF1α.207 In gastric cancer, epigenetic regulation of Reptin expression 
may also exist.  
Except for regulating hTERT transcription and clonogenic potential of gastric cancer cells, 
there are no reports about other roles of Reptin in gastric cancer, for example in invasion 
and metastasis; in malignant transformation, in metabolism: Reptin is involved in the  
regulation of glucose transporter 4 (GLUT4)208 which is implicated in the cancer 
development;209 DNA repair and transcription regulation of oncogenic transcription 
factors. 
Targeting telomerase by inhibiting the regulators of hTERT is an also interesting avenue 
to explore. It is shown in human hepatocellular carcinoma that targeting Reptin inhibited 
the tumor growth in xenografts.192 Identification of small molecule inhibitors for Pontin 
provides promising indication for the exploration of inhibitors for Reptin.210 It can be 
achieved by antagonizing its ATPase activity or by inhibiting its interactions with other 
proteins. 
4.2 Investigating roles of FoxM1 in cancer and targeting FoxM1 in 
cancer therapy 
In study II we showed that targeting FoxM1 reduced telomerase activity, c-Myc 
expression and led to cellular senescence in gastric cancer cells. Extensive evidence 
shows that FoxM1 can regulate a multitude of essential oncogenic functions. FoxM1 is 
associated with a number of hallmarks of cancer such as: angiogenesis, proliferation, 
senescence regulation and metastasis, tumorigenesis. It is of great interest to explore other 
34 
 
roles of FoxM1 in tumor pathogenesis. One of them is the link between FoxM1 and 
regulation of metabolism. Sufficient metabolites are the prerequisite of cell proliferation. 
The link between metabolism and proliferation regulator FoxM1 may be involved in the 
coordination of signals during carcinogenesis. Preliminary evidence is as follows. Firstly, 
FoxM1 expression can be triggered by oxidative stress in the cells. Metabolism process is 
one major source of the reactive oxygen species produced inside the cells. FoxM1 might 
be involved in metabolism regulation. Secondly, link between oncogenic metabolic 
signaling and FoxM1 signaling is shown by experimental study. There is a study showing 
glycolysis enzyme phosphoglycerate dehydrogenase implicated in tumorigenesis211 can 
promote the proliferation and invasion of glioma cells through stabilizing FoxM1.212  
Further investigation is necessary to decipher the interaction mechanism. 
Third, it is interesting to know the mechanism of FoxM1 up regulation in gastric cancer. 
In human squamous cell carcinoma, up-regulation of FoxM1 is an early event during 
carcinogenesis.213 And nicotine from tobacco consumption can promote the effect of 
FoxM1 in malignant transformation of human oral keratinocytes. 213  H.pylori infection is 
associated with the carcinogenesis of gastric cancer. Experimental investigation is needed 
to understand if H.pylori is implicated in the aberrant activation of FoxM1 during early 
stage of gastric cancer development. The hints are as follows. Firstly, oxidative stress 
caused by H.pylori infection plays key role in pathogenesis of gastric cancer.214 Oxidative 
stress can induce the  expression of  FoxM1.79  FoxM1 can promote proliferation of 
gastric cancer cells and regulate c-Myc and telomerase activity as shown in the current 
study. Secondly, FoxM1 can be regulated by Gli-transcription factors in sonic hedgehog 
(Shh) signaling.88 H.pylori infection can cause the activation of Shh signaling by 
secreting virulence factor CagA.215 FoxM1 is likely a downstream factor in the H.pylori 
infection process. 
Meanwhile, it is warranted to develop therapeutic methods for targeting FoxM1. There 
are studies showing the potential of targeting FoxM1 in animal models. For example, 
FoxM1b deficient mice are resistant to developing hepatocellular carcinoma induced by 
carcinogen.81 In human pancreatic liver and colon cancer cells, inhibition of FoxM1 can 
increase the sensitivity of tumor cells to DNA damage agents induced cell death. It is 
promising to develop treatment strategy by inhibiting FoxM1.216 Combination of 
chemotherapeutic drug together with FoxM1 inhibitor can be a method. As shown in the 
current study, FoxM1 inhibition can cause permanent cell cycle arrest which is one of the 
major aims in tumor therapy. 
4.3 Combination therapy based on sorafenib and targeting tumor 
microenvironment 
Combination of tyrosine kinase inhibitor with other treatments such as chemotherapy can 
increase the treatment efficiency of tyrosine kinase inhibitors. In the current study, the co-
administration of sorafenib with Bcl-2 antagonist ABT737 was found to be more efficient 
in killing both non-metastatic and metastatic prostate cancer cells than sorafenib alone. It 
was also shown that the treatment efficiency of sorafenib was dramatically enhanced 
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when combined with chemotherapy drug.217 The synergistic effect of sorafenib with 
ABT737 was also reported in treatment of hepatocellular cancer cells, 218 chronic 
myelogenous leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic 
leukemia cells.219 The current study provides an important piece of evidence for tyrosine 
kinase combination therapy. 
Tumor microenvironment is participating in the regulation of most hallmarks of cancer. 
Components of the tumor microenvironment including activated fibroblasts, recruited 
macrophages and remolded extracellular matrix components actively contribute to the 
epithelial cell-stroma cell crosstalk. One important role of tumor stroma is to provide 
protection to tumor cells against chemotherapy. Targeting tumor microenvironment has 
become a novel therapeutic strategy. Understanding the contributors is the prerequisite of 
the specific treatment. Diverse growth factors, cytokines and chemokines can be involved 
in the protective effect transduced from cancer associated fibroblasts. Different strategies 
are proposed for targeting CAFs. Tyrosine kinase inhibitor is a promising candidate 
because the activation of fibroblasts in tumor stroma largely depends on the tyrosine 
kinas signaling pathways. The effect of sorafenib in reversing the tumor 
microenvironment protection was also shown in multiple myeloma.150 
4.4 Understanding the regulation and role of non-canonical autophagy 
in cancer  
The finding of ATG5-independent autophagy in prostate cancer cells may provoke the 
investigation of autophagy mechanism in other types of malignancies. DU145 cells are a 
suitable model for this investigation because they do not express ATG5. In ATG5-
independent autophagy, several questions are left unanswered. For example, the 
membrane source of the ATG5-independent autophagy and how traffic of membrane 
structures is regulated. It has been found that in MEFs, the membrane source of ATG5-
independent autophagosomes is the trans-Golgi network and late endosomes.201 It is 
interesting to know the answer in tumor cells. It is reasonable to speculate that in prostate 
cancer cells in vivo, ATG5-dependent autophagy and ATG5-independent autophagy 
coexists. They might be induced by different stimuli under different contexts. They may 
also have different functions. Also different regulatory machinery can be involved in the 
regulations. To have a complete picture, further investigations are needed. Our study also 
indicates that defining the autophagy pattern in patients is important for the autophagy 
modulator therapy in clinic. 
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